News

Many participants in the mobile screening program have never previously seen a dermatologist.

Oral therapies may provide more widespread and effective repigmentation, especially in extensive nonsegmental vitiligo.

A retrospective claims analysis found that nearly half of patients newly diagnosed with vitiligo by a dermatologist did not initiate therapy, and those who did showed low persistence across treatment categories.

A rare case shows HAE with chronic spontaneous urticaria; non-itchy facial swelling despite omalizumab signals C4 and C1-INH testing.

Work productivity loss fell from 44.3% at baseline to 19.0% at week 52 in the total study population, representing a clinically meaningful reduction in occupational impairment over the full treatment period.

Two oral BTK inhibitors and two injectable biologics demonstrated superior efficacy over placebo in a systematic review of 16 CSU trials.

In this episode, Daniel Walker, MD, FAAD, explains how GLP-1 drugs may be effective for psoriasis and HS, linking skin inflammation with weight and heart health.

Although dermatologists are not expected to routinely prescribe GLP-1 drugs, they are increasingly encountering cutaneous effects, especially hair loss and facial volume loss.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Late-breaking data presented at AAD 2026 showed that upadacitinib 15 mg produced statistically significant, progressively improving repigmentation in adults and adolescents with non-segmental vitiligo through 48 weeks.

The guidelines formalize a stepwise treatment approach ranging from emollients and topical steroids to systemic therapies.

Phase 2/3 brepocitinib trial will target moderate to severe LPP, aiming to calm inflammation and symptoms and potentially deliver the first FDA-approved systemic option.

GLP-1 agonists may aid psoriasis, wound healing, and cardiometabolic health—Daniel Walker, MD, FAAD, explains why dermatologists should start to pay attention.

New studies suggest tattoo pigments migrate to lymph nodes, complicate skin exams, and may raise lymphoma risk—what dermatologists now watch for.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

David Oberlin, MD, shares tips for integrating AAD insights and lessons into the clinic to improve patient care.

Kristen Lo Sicco, MD, shares why scarring alopecia can’t wait as LPP demands early treatment to prevent permanent hair loss amid limited FDA-approved options.

Among systemic-experienced patients, delgocitinib cream still achieved statistically significant efficacy advantages over cream vehicle across all measured outcomes.

GLP-1 therapy may calm psoriasis and hidradenitis suppurativa beyond weight loss, and holistic metabolic care can address aesthetic concerns, according to Walker.

Applications are now open for Allergan Aesthetics' women's entrepreneurship initiative, which provides coaching, community, and grants of up to $20,000 to qualifying business owners.

Dermatologists are exploring GLP-1 drugs for psoriasis and HS, but evidence is early—weight-loss benefits may help as add-ons, not replacements.

The combination of rapid onset and durable response positions zumilokibart as a potentially attractive first-line biologic option.

A cross-sectional study of 403 acne patients found that higher impulsivity scores were significantly associated with both the presence and severity of acne scars.

This review of the latest dermatological studies includes insights on acne in women with hyperandrogenism, fractional CO2 laser and gold microneedling for scarring, oxygen plasma acne treatment, and more.

At AAD 2026, Lauren Madigan, MD, presented long-term PIONEER trial extension data and urged clinicians to sharpen their recognition of 2 clonally driven inflammatory diseases: indolent systemic mastocytosis and VEXAS syndrome.

A new study details the effectiveness of non-invasive HFUS and CDFI technologies for revealing residual disease not captured by clinical evaluation in patients with acne.